Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 37, Issue 7, 2006, Pages 635-640

  Andersen, J ^a   Heilmann, C ^a   Jacobsen, N ^a   Nielsen, C ^a   Bendtzen, K ^a   Müller, Klaus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Allogenic stem cell transplantation; Chemotheraphy; Conditioning; IL 1Ra; Inflammatory cytokines; STNFRI and II

Indexed keywords

BUSILVEX; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFLAMMATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR; WHOLE BODY RADIATION;

ADULT; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SIBLINGS; STEM CELL TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33645218180     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705295     Document Type: Article

References (30)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895-902.
2. Loberiza F. International Bone Marrow Transplant Registry Newsletter 2003.
3. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
4. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft versus host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
5. Ferrara JLM, Antin JH. The pathophysiology of graft-versus-host d isease. In: Thomas ED, Blume K, Forman S (eds). Bone Marrow Transplantation. Blackwell Science: Berlin, 1999, pp 305-315.
6. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermuller J, Thierfelder S, Kaul M et al. Role of tumour necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234-1236.
7. Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS et al. Differential roles of IL-1 and TNFα on graft-versus-host disease and graft versus leukemia. J Clin Invest 1999; 104: 459-467.
8. Remberger M, Ringden O, Markling L. TNFα levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995; 15: 99-104.
9. Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
10. Holler E, Kolb HJ, Mittermuller J, Kaul M, Ledderose G, Duell T et al. Modulation of graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha release in the course of pretransplant conditioning: Role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood 1995; 86: 890-899.
11. Abdallah AN, Boiron JM, Attia Y, Cassaigne A, Reiffers J, Iron A. Plasma cytokines in graft versus host disease and complications following bone marrow transplantation. Hematol Cell Ther 1997; 39: 27-32.
12. Chasty RC, Lamb WR, Gallati H, Roberts TE, Brenchley PE, Yin JA. Serum cytokine levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12: 331-336.
13. Sakata N, yasui M, Okamura T, Inoue M, Yumura-Yagi K, Kawa K. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: The ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001; 27: 1153-1161.
14. Takatsuka H, Takemoto Y, Yamada S, Wada H, Tamura S, Fujimori Y et al. Complications after bone marrow transplantation are manifestations of systemic inflammatory response syndrome. Bone Marrow Transplant 2000; 26: 419-426.
15. Sardas OS, Beksac M, Koc H, Ilhan O, Akan H, Gurman G. Tumor necrosis factor alpha in human bone marrow recipients. Blood 1990; 76: 2639-2640.
16. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev Immunol 2002; 2: 364-371.
17. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nature Rev Immunol 2002; 2: 37-45.
18. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-916.
19. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its receptors. J Exp Med 1992; 175: 323-329.
20. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumour necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845-4849.
21. Giradin E, Roux-Lombard P, Gran GE, Suter P, Gallati H, Dayer JM. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992; 76: 20-23.
22. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG. Tumour necrosis factor receptor type II 196 M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft versus host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76: 1742-1749.
23. Andersen LS, Petersen J, Bendtzen K. Production of interleukin (IL)-1b, IL-1 receptor antagonist and IL-10 by blood mononuclear cells in chronic arthritis. Cytokine 2000; 12: 62-68.
24. Or R, Kalinkowich A, Nagler A, Weisman Z, Naparstek E, Weiss L et al. Soluble tumor necrosis factor receptors: A possible prognostic marker for bone marrow transplantation related complications. Cytokines Mol Ther 1996; 2: 243-250.
25. Kashuap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493-500.
26. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF et al. Cytokine gene polymorphism in human disease: On-line databases. Genes Immunity 1999; 1: 3-19.
27. Morita C, Horiuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu Y et al. Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the japanese. Arthritis Rheum 2001; 44: 2819-2827.
28. Shamim Z, Ryder LP, Heilmann C, Madsen HO, Svejgaard A, Jacobsen N et al. Genetic polymorphisms in the genes encoding human interleukin-7α. Biol Blood Marrow Transplant 2005; 11: 1.
29. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-680.
30. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64: 553-558.